CD8A and neoplasm: Targeted immunotherapies to inhibit immune checkpoints PD-1/PD-L1 or cytotoxic T lymphocyte antigen 4 for restoring exhausted CD8+ T-cell activity or inducing CD4+ T lymphocyte expansion hold promise in human cancer treatment; however, a limited number of tumor patients have received clinical benefits mainly due to acquired therapeutic resistance (209–212).